Study of Anti-Tumor Immunity and Tissue Resident Memory Cell Development by NKG2D and Ribosomal Protein S6 Signaling in T cells
T 细胞中 NKG2D 和核糖体蛋白 S6 信号传导的抗肿瘤免疫和组织驻留记忆细胞发育研究
基本信息
- 批准号:10363630
- 负责人:
- 金额:$ 36.92万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-14 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:AccreditationAgonistAutologousAutomobile DrivingCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCD8B1 geneCellsCellular StructuresCertificationClinical TrialsDataDefectDevelopmentEffector CellEngineeringFRAP1 geneFailureFlow CytometryGene ExpressionGenerationsGeneticGoalsHumanImmuneImmunologic MemoryImmunotherapyImpairmentIndividualIntentionInterleukin-15InterventionMaintenanceMalignant NeoplasmsMemoryMicroscopicModelingMolecularMonoclonal AntibodiesMusPathway interactionsPharmacologyPhasePhosphorylationPlayProcessProductionProtein BiosynthesisRepressionRibosomal Protein S6RoleSignal TransductionSkinStat5 proteinT cell responseT memory cellT-LymphocyteTSC1 geneTestingTherapeuticThymus GlandTimeTransgenic OrganismsTumor ImmunityTumor TissueWestern BlottingWorkbasecell growth regulationclinically relevantexperimental studygrowth factor receptor-bound protein 2inhibitormelanomamouse modelpatient derived xenograft modelprecursor cellreceptorreconstitutionresponsetranscription factortumortumor growthtumor immunology
项目摘要
In the field of tumor immunology, while the generation and maintenance of anti-tumor CD8 T cell
memory responses are considered crucial for the long-term host survival, the basic tenets of memory
formation remain to be established. We propose to study and manipulate the CD8 T cell
NKG2D/DAP10 ribosomal protein S6 (rpS6) pathway as a means to generate durable and protective
anti-tumor immunity. The scientific premise of this study is derived from our work demonstrating that
NKG2D signaling provides CD8 T cells with pro-memory signals. We hypothesize that NKG2D,
through finely tuned DAP10PI3K/Grb2 signaling (as NKG2D cannot signal by itself, instead uses
DAP10PI3K/Grb2 as signaling adaptor), activates rpS6 resulting in the development of functionally
capable CD8 memory T cells. This proposal will define the underlying players required for rpS6
phosphorylation downstream of NKG2D/DAP10 and its implications in the development of
immunological memory against tumors including TRM cells. Here we will conduct proof-of-concept
tests utilizing human and mouse tumors, with the intention of preparing for a clinical trial.
SA1: TO DETERMINE THE MOLECULAR CONTRIBUTORS OF NKG2D-DAP10 INDUCED
PHOSPHORYLATION OF rpS6
SA2. TO DETERMINE THE ROLE OF NKG2D/DAP10PI3K/GRB2 IN THE DEVELOPMENT OF
TRADITIONAL MEMORY RESPONSES AND SKIN TRM CELLS AGAINST MELANOMA.
SA3. TO EVALUATE THE THERAPEUTIC POTENTIAL OF MANIPULATING THE
DAP10/rpS6 PATHWAY IN CD8 T CELLS
在肿瘤免疫学领域,抗肿瘤CD 8 T细胞的产生和维持,
记忆反应被认为对宿主的长期生存至关重要,这是记忆的基本原则。
组建尚待确定。我们建议研究和操纵CD 8 T细胞
NKG 2D/DAP 10通过核糖体蛋白S6(rpS 6)途径产生持久的保护性
抗肿瘤免疫这项研究的科学前提来自于我们的工作,
NKG 2D信号传导为CD 8 T细胞提供促记忆信号。我们假设NKG 2D,
通过微调的DAP 10 PI 3 K/Grb 2信号(因为NKG 2D不能自己发送信号,而是使用
DAP 10 PI 3 K/Grb 2作为信号转导衔接子),激活rpS 6,导致功能性的
CD 8记忆T细胞该提案将定义rpS 6所需的底层参与者
NKG 2D/DAP 10下游的磷酸化及其在发展中的意义
针对肿瘤的免疫记忆,包括TRM细胞。在这里,我们将进行概念验证
利用人类和小鼠肿瘤进行测试,目的是为临床试验做准备。
SA 1:确定NKG 2D-DAP 10诱导的
rpS 6的磷酸化
SA 2.为了确定NKG 2D/DAP 10 PI 3 K/GRB 2在细胞生长发育中的作用,
黑色素瘤的传统记忆反应和皮肤TRM细胞。
SA 3.为了增强操纵
CD 8 T细胞中的DAP 10/rpS 6通路
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jose Alejandro Guevara-Patino其他文献
Jose Alejandro Guevara-Patino的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jose Alejandro Guevara-Patino', 18)}}的其他基金
Exploratory Study of T Cell Skin Trafficking and the Role of NKG2D Signaling; Implications in Vitiligo and Melanoma
T 细胞皮肤贩运和 NKG2D 信号传导作用的探索性研究;
- 批准号:
10608358 - 财政年份:2023
- 资助金额:
$ 36.92万 - 项目类别:
Study of Anti-Tumor Immunity and Tissue Resident Memory Cell Development by NKG2D and Ribosomal Protein S6 Signaling in T cells
T 细胞中 NKG2D 和核糖体蛋白 S6 信号传导的抗肿瘤免疫和组织驻留记忆细胞发育研究
- 批准号:
10448715 - 财政年份:2021
- 资助金额:
$ 36.92万 - 项目类别:
Study of Anti-Tumor Immunity and Tissue Resident Memory Cell Development by NKG2D and Ribosomal Protein S6 Signaling in T cells
T 细胞中 NKG2D 和核糖体蛋白 S6 信号传导的抗肿瘤免疫和组织驻留记忆细胞发育研究
- 批准号:
10555239 - 财政年份:2021
- 资助金额:
$ 36.92万 - 项目类别:
TCR/DAP10 chimera as a means to attaining persistent anti-tumor T cell responses
TCR/DAP10 嵌合体作为获得持久抗肿瘤 T 细胞反应的手段
- 批准号:
8918555 - 财政年份:2014
- 资助金额:
$ 36.92万 - 项目类别:
Rescuing Anti-tumor Responses of TCR-Td T Cells by NKG2D-stimulation
通过 NKG2D 刺激挽救 TCR-Td T 细胞的抗肿瘤反应
- 批准号:
8672173 - 财政年份:2014
- 资助金额:
$ 36.92万 - 项目类别:
Rescuing Anti-tumor Responses of TCR-Td T Cells by NKG2D-stimulation
通过 NKG2D 刺激挽救 TCR-Td T 细胞的抗肿瘤反应
- 批准号:
8909077 - 财政年份:2014
- 资助金额:
$ 36.92万 - 项目类别:
Rescuing Anti-tumor Responses of TCR-Td T Cells by NKG2D-stimulation
通过 NKG2D 刺激挽救 TCR-Td T 细胞的抗肿瘤反应
- 批准号:
9313795 - 财政年份:2014
- 资助金额:
$ 36.92万 - 项目类别:
TCR/DAP10 chimera as a means to attaining persistent anti-tumor T cell responses
TCR/DAP10 嵌合体作为获得持久抗肿瘤 T 细胞反应的手段
- 批准号:
8756661 - 财政年份:2014
- 资助金额:
$ 36.92万 - 项目类别:
Impact of AICD on TCR Transduced T Cells for Adoptive Immunotherapy
AICD 对用于过继免疫治疗的 TCR 转导 T 细胞的影响
- 批准号:
8555360 - 财政年份:2011
- 资助金额:
$ 36.92万 - 项目类别:
Disparate suppression of naive effector and memory T cells in tumor-bearing hosts
荷瘤宿主中幼稚效应 T 细胞和记忆 T 细胞的不同抑制
- 批准号:
7537204 - 财政年份:2008
- 资助金额:
$ 36.92万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 36.92万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 36.92万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 36.92万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 36.92万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 36.92万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 36.92万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 36.92万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 36.92万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 36.92万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 36.92万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




